For example, Zuardi et al. [65,66] did not find CBD monotherapy (up to 1,280 mg) to be effective relative to placebo in a case-series of bipolar mania and treatment-resistant schizophrenia patients. The gene discussed is OPN1MW; the disease is schizophrenia.